<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040637</url>
  </required_header>
  <id_info>
    <org_study_id>0067</org_study_id>
    <nct_id>NCT01040637</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation</brief_title>
  <official_title>A Phase 1/Phase 2, Randomized, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Effect on Opioid Analgesia of TD-1211 Administered Orally to Healthy Volunteers and to Assess the Safety, Pharmacokinetics, and Effect on Bowel Movements in Subjects With Opioid-Induced Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma Antibiotics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      TD-1211 in healthy subjects and activity in subjects with opioid-induced constipation (OIC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability in healthy subjects and activity in subjects with opioid-induced constipation</measure>
    <time_frame>Daily pre and post dose assessments throughout the duration of the study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the multiple dose pharmacokinetics of TD-1211 following oral administration</measure>
    <time_frame>Daily pre and post dose assessments throughout the duration of the study period</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Healthy</condition>
  <condition>Opioid-induced Constipation</condition>
  <arm_group>
    <arm_group_label>TD-1211 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1211 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1211 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1211 dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1211 OIC dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1211 OIC dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1211 OIC dose leve 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1211 OIC dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1211 OIC dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ascending doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Dose level 1</description>
    <arm_group_label>TD-1211 dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Dose level 2</description>
    <arm_group_label>TD-1211 dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Dose level 3</description>
    <arm_group_label>TD-1211 dose level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Dose Level 4</description>
    <arm_group_label>TD-1211 dose level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Ascending doses</description>
    <arm_group_label>TD-1211 OIC dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Ascending doses</description>
    <arm_group_label>TD-1211 OIC dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Ascending doses</description>
    <arm_group_label>TD-1211 OIC dose leve 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Ascending doses</description>
    <arm_group_label>TD-1211 OIC dose level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1211</intervention_name>
    <description>Ascending doses</description>
    <arm_group_label>TD-1211 OIC dose level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ascending doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between 18 and 65 years of age, inclusive

          -  Healthy subjects and subjects with documented OIC on stable opioid regimen

          -  Willingness to stop all laxatives throughout the OIC screening and treatment period

        Exclusion Criteria:

          -  Any clinically significant finding in healthy subjects

          -  Have participated in another clinical trial of an investigational drug 30 days prior
             to screening

          -  History of chronic constipation prior to opioid therapy in OIC subjects

          -  Active medical disorders associated with diarrhea or intermittent loose stools in OIC
             subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Unit</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Unit</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Unit</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2009</study_first_posted>
  <disposition_first_submitted>February 8, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 13, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2013</disposition_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

